Golimumab in patients with active rheumatoid arthritis despite treatment with methotrexate

被引:235
作者
Kay, Jonathan [1 ,2 ]
Matteson, Eric L. [3 ]
Dasgupta, Bhaskar [4 ]
Nash, Peter [5 ,6 ]
Durez, Patrick [7 ]
Hall, Stephen [8 ]
Hsia, Elizabeth C. [9 ,10 ]
Han, John [9 ]
Wagner, Carrie [9 ]
Xu, Zhenhua [9 ]
Visvanathan, Sudha [9 ]
Rahman, Mahboob U. [9 ,10 ]
机构
[1] Massachusetts Gen Hosp, Rheumatol Unit, Boston, MA 02114 USA
[2] Harvard Univ, Sch Med, Boston, MA USA
[3] Mayo Clin, Coll Med, Rochester, MN USA
[4] Southend Univ Hosp, W Cliff, Essex, England
[5] Nambour Hosp, Brisbane, Qld, Australia
[6] Univ Queensland, Brisbane, Qld, Australia
[7] Catholic Univ Louvain, Clin Univ St Luc, B-1200 Brussels, Belgium
[8] Cabrini Med Ctr, Malvern, Vic, Australia
[9] Centocor Res & Dev Inc, Malvern, PA USA
[10] Univ Penn, Sch Med, Philadelphia, PA 19104 USA
来源
ARTHRITIS AND RHEUMATISM | 2008年 / 58卷 / 04期
关键词
D O I
10.1002/art.23383
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Objective. To assess the efficacy, safety, and pharmacology of subcutaneous administration of golimumab in patients with active rheumatoid arthritis (RA) despite treatment with methotrexate (MTX). Methods. Patients were randomly assigned in a double-blinded manner to receive injections of placebo plus MTX or 50 mg or 100 mg golimumab every 2 or 4 weeks plus MTX through week 48. Patients originally assigned to receive injections every 2 weeks had the interval increased to every 4 weeks starting at week 20. The primary end point was the proportion of patients meeting the American College of Rheumatology 20% improvement criteria (achieving an ACR20 response) at week 16. The study was powered to detect a difference in the primary end point when the combined golimumab groups and at least I of the individual dose groups were compared with placebo. Results. The primary end point was attained. Sixty-one percent of patients in the combined golimumab plus MTX dose groups achieved an ACR20 response at week 16 compared with 37% of patients in the placebo plus MTX group (P = 0.010). In addition, 79% of patients in the group receiving 100 mg golimumab every 2 weeks achieved an ACR20 response (P < 0.001 versus placebo). Through week 20 (after which patients receiving placebo were switched to active infliximab therapy), serious adverse events were reported in 9% of patients in the combined golimumab groups and in 6% of patients in the placebo group. Conclusion. Golimumab plus MTX effectively reduces the signs and symptoms of RA and is generally well tolerated in patients with an inadequate response to MTX.
引用
收藏
页码:964 / 975
页数:12
相关论文
共 18 条
[1]   THE AMERICAN-RHEUMATISM-ASSOCIATION 1987 REVISED CRITERIA FOR THE CLASSIFICATION OF RHEUMATOID-ARTHRITIS [J].
ARNETT, FC ;
EDWORTHY, SM ;
BLOCH, DA ;
MCSHANE, DJ ;
FRIES, JF ;
COOPER, NS ;
HEALEY, LA ;
KAPLAN, SR ;
LIANG, MH ;
LUTHRA, HS ;
MEDSGER, TA ;
MITCHELL, DM ;
NEUSTADT, DH ;
PINALS, RS ;
SCHALLER, JG ;
SHARP, JT ;
WILDER, RL ;
HUNDER, GG .
ARTHRITIS AND RHEUMATISM, 1988, 31 (03) :315-324
[2]   Clinical response to adalimumab: relationship to anti-adalimumab antibodies and serum adalimumab concentrations in rheumatoid arthritis [J].
Bartelds, Geertje M. ;
Wijbrandts, Carla A. ;
Nurmohamed, Michael T. ;
Stapel, Steven ;
Lems, Willem F. ;
Aarden, Lucien ;
Dijkmans, Ben A. C. ;
Tak, Paul Peter ;
Wolbink, Gerrit Jan .
ANNALS OF THE RHEUMATIC DISEASES, 2007, 66 (07) :921-926
[3]   A comparison of etanercept and methotrexate in patients with early rheumatoid arthritis [J].
Bathon, JM ;
Martin, RW ;
Fleischmann, RM ;
Tesser, JR ;
Schiff, MH ;
Keystone, EC ;
Genovese, MC ;
Wasko, MC ;
Moreland, LW ;
Weaver, AL ;
Markenson, J ;
Finck, BK .
NEW ENGLAND JOURNAL OF MEDICINE, 2000, 343 (22) :1586-1593
[4]   Immunogenicity, efficacy and adverse events of adalimumab in RA patients [J].
Bender, Niko K. ;
Heilig, Christoph E. ;
Droell, Benjamin ;
Wohlgemuth, Jessica ;
Armbruster, Franz-Paul ;
Heilig, Bernhard .
RHEUMATOLOGY INTERNATIONAL, 2007, 27 (03) :269-274
[5]   Antibody humanization: a case of the 'Emperor's new clothes'? [J].
Clark, M .
IMMUNOLOGY TODAY, 2000, 21 (08) :397-402
[6]   AMERICAN-COLLEGE-OF-RHEUMATOLOGY PRELIMINARY DEFINITION OF IMPROVEMENT IN RHEUMATOID-ARTHRITIS [J].
FELSON, DT ;
ANDERSON, JJ ;
BOERS, M ;
BOMBARDIER, C ;
FURST, D ;
GOLDSMITH, C ;
KATZ, LM ;
LIGHTFOOT, R ;
PAULUS, H ;
STRAND, V ;
TUGWELL, P ;
WEINBLATT, M ;
WILLIAMS, HJ ;
WOLFE, F ;
KIESZAK, S .
ARTHRITIS AND RHEUMATISM, 1995, 38 (06) :727-735
[7]   MEASUREMENT OF PATIENT OUTCOME IN ARTHRITIS [J].
FRIES, JF ;
SPITZ, P ;
KRAINES, RG ;
HOLMAN, HR .
ARTHRITIS AND RHEUMATISM, 1980, 23 (02) :137-145
[8]   Infliximab and methotrexate in the treatment of rheumatoid arthritis [J].
Lipsky, PE ;
van der Heijde, DMFM ;
St Clair, EW ;
Furst, DE ;
Breedveld, FC ;
Kalden, JR ;
Smolen, JS ;
Weisman, M ;
Emery, P ;
Feldmann, M ;
Harriman, GR ;
Maini, RN .
NEW ENGLAND JOURNAL OF MEDICINE, 2000, 343 (22) :1594-1602
[9]   Etanercept therapy in rheumatoid arthritis - A randomized, controlled trial [J].
Moreland, LW ;
Schiff, MH ;
Baumgartner, SW ;
Tindall, EA ;
Fleischmann, RM ;
Bulpitt, KJ ;
Weaver, AL ;
Keystone, EC ;
Furst, DE ;
Mease, PJ ;
Ruderman, EM ;
Horwitz, DA ;
Arkfeld, DG ;
Garrison, L ;
Burge, DJ ;
Blosch, CM ;
Lange, MLM ;
McDonnell, ND ;
Weinblatt, ME .
ANNALS OF INTERNAL MEDICINE, 1999, 130 (06) :478-+
[10]  
Pendley C, 2003, CURR OPIN MOL THER, V5, P172